Nimbus Therapeutics

About Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company focused on designing and developing small molecule medicines with high selectivity to improve patients' lives. They emphasize meticulous choices in targets, molecules, and partnerships, backed by a track record of success and world-class expertise.

Products & Services

Small Molecule Medicines:Highly selective medicines targeting oncology, immunology, and metabolic indications.

NDI-219216:A novel WRN inhibitor for MSI-H tumors, currently in first-in-human clinical trials.

Specialties

Target Selection Computational Drug Design Translational Medicine Clinical Development Small Molecule Medicines Oncology Immunology Metabolic Indications

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Financing T: - FT: Private Financing	A: 210000000 MR: - FA: $210 million FAN: 210000000	D: 2023-09-06 FD: 2023-09-06	11 investors

Private Financing Latest

2023-09-06

$210.0M

11 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Leela Dodda

Director, Computational Chemistry

S

Samantha Carreiro

Senior Scientist, DMPK

D

Derun Li

Senior Director, Medicinal Chemistry

S

Scott Edmondson

Senior Vice President, Head of Chemistry

A

Abbas Kazimi

Chief Executive Officer

C

Christine Loh

Senior Vice President, Head of Biology

View 26 more team members with Pro

Unlock Full Team Directory

Recent News